C-Change Board Adopts Smoking Resolution

In the past decade, many U.S. jurisdictions, and now several European nations, have adopted legislation prohibiting smoking in public buildings and outdoor spaces. On January 13, 2005, the C-Change Board of Directors unanimously adopted a policy requiring that, beginning in 2006, all C-Change semi-annual meetings and sponsored conferences are to convene in smoke-free cities or jurisdictions.

As part of the same resolution, C-Change members and partners will be asked to consider convening major conferences of their organizations in smoke-free jurisdictions in the future. This Call to Action will be issued at the May 20-21, 2005, Semi-Annual Meeting. The resolution can be viewed in full at www.c-changetogether.org.

C-Change’s Prevention and Early Detection Team recommended the policy, in conjunction with the Tobacco Control Team. Board member Dileep Bal developed and introduced the resolution.

Unless the District of Columbia adopts smoke-free legislation within the next year, future C-Change meetings will be held in other locations around the country. For more information about smoke-free jurisdictions, see http://www.no-smoke.org/pdf/100ordlisttabs.pdf.

On Monday, March 14, 2005, C-Change’s Cancer Research Team hosted an educational Hill Briefing on “Funding Cancer Research: Progress, Opportunities, and the Role of Government” at the Rayburn House Office Building in Washington, DC. The Briefing attracted attendees representing the U.S. House of Representatives and Senate, lobbyists, and C-Change co-sponsors to participate. Three C-Change members led the program: Tom Curran, MD, a neurobiologist at St. Jude Children’s Research Hospital; Harold, “Hal,” Moses, MD, of the Vanderbilt-Ingram Cancer Center and Vice-Chair of the Cancer Research Team; and honorary C-Change member Sam Donaldson of ABC News.

The program explored key questions such as “How is cancer research funded?” and “What are we getting from our investment?” As the government faces increasing budgetary pressure, staffers were interested to learn how limited research dollars are being leveraged and spent. The topic was chosen based on feedback from Hill staffers at the last Briefing held in Fall 2004.

Hal Moses pointed out that RO1 Grants fuel academic medical centers, which serve as the innovation engine for research. He noted that approximately 45% of the NCI budget has been dedicated to research project grants over the past five years, awarding more than 5,000 grants per year. But, Moses said that, due to the rigor of the peer review process and the limited amount of funding, the acceptance rate for scientists applying for grant awards has dropped from approximately 35% to 20% or less in recent years. Moses asserted that in order to maintain research momentum and to continue to attract the best and the brightest people to cancer research, the success rate must be kept at a sufficiently high level (25 to 40 percent range) to assure a reasonable chance at securing funding.

Note: Date Change
Fall Semi-Annual Meeting
October 14-15, 2005
Renaissance Hotel
Washington, D.C.
ASSURING THAT WE SEE CHANGE

It seems to me that there are several parallels between human and organizational development. Like human beings, organizations must be nurtured, yet disciplined in their choices to achieve their full potential. C-Change’s embryonic stage consisted of our early years as the National Dialogue on Cancer, a time when we envisioned common causes across sectors and members.

In March 2004, C-Change made its public debut at the National Press Club. We were introduced as a new 501c3 whose mission was “to leverage the expertise and resources of our membership to eliminate cancer as a public health problem at the earliest possible time.” As we changed our name, we charged our teams to move from a focus on dialogue to a focus on action. We issued several calls to action to our membership to harness our collective potential. Now, as a more mature body, it is time for us to create a strategic plan to assure that discipline needed to achieve our full potential.

As a prelude to our planning process, we acknowledged that our mission and vision are essential to conquering cancer. With respect for our past, and gratitude for our accomplishments, we are intent on creating a dynamic future. Our goal is to create a thoughtful document to guide priorities, determine allocation of resources, and promote balance across the interests and resources of our three sectors of membership.

We are defining our strategic imperatives around preventing, detecting, treating and managing cancer. Ironically, the enormous breadth and depth of our membership makes it challenging to determine the unique role of C-Change in achieving these imperatives. As we identify issues best suited to our attention, we believe they should be large scale and complex in nature. The issues should be multi-sector, multi-factorial, and fundamental to the cancer world. Our unique issues should be those that are unlikely to be resolved without intervention or those that will be notably accelerated from a C-Change focus.

Our belief is that C-Change should be generating approaches that optimize the use of existing knowledge and create new knowledge. We should focus on those issues that require new intellectual approaches to improve our structures, processes and outcomes. The sustained focus of our multi-sector leaders and experts will enable achievements that are not possible by any single organization or sector.

In addition to our uniqueness, we must also address the issue of sustainability. We have adopted a cyclical model to assure our sustainability. After identifying the appropriate strategic imperatives, we will focus on coordinating the efforts of our Members and stakeholders to achieve the imperatives. Then, we must secure the talent, time and funding necessary to support our activities and initiatives. Finally, we must deliver results that insure impact by aligning our Members and stakeholders and delivering our results to the cancer community. The cycle will then repeat itself, hinged on our prior successes, with the identification of new, appropriate strategic imperatives.

The Board of Directors and C-Change staff have begun this strategic planning process. We will share our progress and products with you as they evolve. Please share your ideas and insights with us. This planning will enable us to mature, to move toward our full potential as an organizational body, and for all of us to see change in our abilities to conquer cancer.

Connie
The Semi-Annual Meeting of C-Change is scheduled for May 20-21, 2005, at the Renaissance Hotel in Washington D.C. More detailed information about the program agenda and logistics will be provided in the invitation slated for release in the first week of April.

Who will Pay for Cancer Care & Progress? On Saturday, May 21, multi-sector experts will explore this question and others. Among the panelists will be Fred Frank, Vice Chairman of Lehman Brother’s Global Healthcare Group. Also, Les Silverman, Director Emeritus of McKinsey & Company, will make a return engagement after addressing C-Change at its June 2004 meeting. The discussion will frame the current and future climate for funding cancer research and treatment from private, public, and non-profit sources. This interactive program will explore the implications for the scope and priorities of the cancer agenda as well as opportunities.

In addition to featured speakers and panelists, the Cancer Workforce, Primary Prevention and Early Detection, and Tobacco Control Teams are planning “Calls to Action” – a further test of our mission to “leverage the expertise and resources of our membership to eliminate cancer as a public health problem at the earliest possible time.” The May meeting will also include a kick-off of the Summer Internship Program, led by the Cancer Workforce Team. Additional updates regarding the strategic planning process will be discussed on behalf of the Board of Directors.

Team Activities
Building upon momentum from the November meeting, the seven teams of C-Change will conduct meetings to advance their strategic priorities (see pgs. 7-8 Team News). In response to feedback from many members who serve on multiple teams, the meetings will be spread out through the day on Friday, May 20, to reduce overlapping meetings. A networking reception Friday evening will wrap up the day’s activities.

The Program Work Group continues to seek program content that addresses topical or emerging issues, holds multi-sector appeal, and helps to advance the mission of the organization. If you have suggestions for future meetings, please contact Alison Smith.

C-Change Joins IOM Cancer Policy Forum
On February 18, the National Cancer Policy Forum of the Institute of Medicine’s (IOM) met to discuss and plan for its transition from a Board to a Forum. C-Change is now a member of the Forum and represented by Executive Director Connie Curran. Several C-Change Members are also on the Forum.

Board Appoints New Team Leaders
As a result of the November 2004 election for the Board of Directors, several team leadership positions became vacant. In January 2005, a call for nominations was issued to the membership of C-Change, and the Board has now confirmed the appointments of the following individuals to serve two-year terms as team leaders:

Holly Howe
Chair, Access Team
Executive Director, North American Association of Central Cancer Registries

Lloyd Everson
Vice Chair, Access Team
Vice Chairman of the Board, U.S. Oncology

Ronald Herberman
Chair, Cancer Research Team
Director, University of Pittsburgh Medical Center Cancer Centers

Kevin Lewis
Vice Chair, Prevention & Early Detection Team
Chairman of the Board, Colon Cancer Alliance

Leslie Given
Vice Chair, State Cancer Plans Team
Manager, National Comprehensive Cancer Control Programs (CDC)

The Board of Directors extends its thanks and congratulations to these members for their leadership and continued contribution to the progress of C-Change.

Research Team Leader Needed
The Board of Directors has issued another call for nomination of a Vice-Chair of the Cancer Research Team.

If you are interested, please contact Connie Curran at cocurran@aol.com.
Nominating Committee Balancing Membership

Led by Chairman Charles Balch and Vice Chairman William Roper, the C-Change Nominating Committee is working to balance the composition of the Board, Members, and Partners. The Board is seeking greater balance in the originally conceived spirit of C-Change of equal representation across all sectors. Presently, not-for-profit organizations account for approximately 60 percent of membership.

The Committee and Board will gradually work toward equal sector representation, emphasizing consistently active participation by the most highly qualified individuals and stakeholder organizations. Members who have not been actively participating during the past two years have been asked to reconsider their role with C-Change. The Committee will also examine recruitment and nomination processes.

The Nominating Committee also now represents the three sectors more equally with the following appointments by the Board:

- Gerard Kennealey
  VP Medical Oncology, AstraZeneca
- Gabriel Leung
  President, OSI Oncology
- William Winkenwerder
  Assistant Secretary of Defense for Health Affairs
- Philip Huang
  Director of Cancer Control, Texas State Department of Health Services
- Pearl Moore, Chief Executive of the Oncology Nursing Society, was re-appointed to a final term under the Committee’s new two-term service limit.

NewsNotes

Aldige Honored by ASCP

C-Change Member Carolyn “Bo” Aldige was recently honored by the American Society of Clinical Oncology (ASCO) with its Partners in Progress Award. Aldige is the President and Founder of the Cancer Research and Prevention Foundation, dedicated to preventing cancer through scientific research and educational programs. Congratulations, Bo!

Meet the New Board Members... Healton & Reedy

Cheryl Healton

Cheryl Healton has been elected to a three-year term on the C-Change Board of Directors. Healton is the first president and chief executive officer of the American Legacy Foundation, a groundbreaking public health nonprofit created by the historic Master Settlement Agreement between 46 state attorneys general, five U.S. territories and the tobacco industry.

She has worked tirelessly to further the foundation’s ambitious mission: to build a world where young people reject tobacco and anyone can quit. She has guided the foundation’s highly acclaimed national youth tobacco prevention, counter-marketing campaign, truth®. The campaign has been credited in part with reducing youth smoking prevalence to its current 28-year low.

“I am deeply honored to join the Board of C-Change,” Healton says. “This organization is uniquely positioned to change the face of cancer in America by emphasizing the impact prevention can have on its incidence and treatments on survival. I look forward to contributing to this critical agenda and learning a great deal from my esteemed colleagues.”

Healton is a wife and mother of three, an author, researcher, professor, and public health administrator with more than 25 years experience. She has served on a vast array of national, state, and local conferences, committees and task forces for public health and policy issues, including HIV/AIDS, violence, and alcoholism. A former smoker, Healton is currently writing a book about women and smoking, with common sense strategies to increase successful quit attempts.

Healton holds a doctorate from Columbia University’s School of Public Health and a master’s degree in Public Administration at New York University for health policy and planning. Prior to joining the foundation, she was Head of the Division of Socio-Medical Sciences and Associate Dean for Program Development at Columbia University’s Joseph L. Mailman School of Public Health.

Gary Reedy

Gary Reedy also was elected to a three-year term on the C-Change Board. He serves as Worldwide Vice President, Biopharmaceutical Public Policy and Services with Johnson & Johnson. He is responsible for spearheading initiatives to influence global health policy for the company’s biopharmaceuticals business.

Reedy has been an active Member of C-Change and is a charter member of the CEO Roundtable on Cancer. He played a key role in drafting the Standard as Chair of the CEO Cancer Gold Standard™ Task Force.

“I look forward to working with the other Directors in establishing a very clear vision and plan and then seeing the whole body of C-Change engaged in its execution,” Reedy says. “There is great potential because of the incredible talent and resources within the Membership that we just need to focus our efforts for success.”

Reedy began his career with Johnson & Johnson in 1993 as Group Director of Marketing for Janssen Pharmaceutica. He also was a founding member of Johnson & Johnson Health Care Systems, where he served as Vice President of Marketing before joining Ortho Biotech as Vice President of Sales & Marketing in 1996. Reedy was appointed President of Ortho Biotech in May 2000, with commercial responsibility for both the United States and Canada.

With more than 26 years of domestic and international experience in the pharmaceutical and biotechnology industry, Reedy also held positions at SmithKline Beecham and Centocor before joining Johnson & Johnson.

He is a member of the American Cancer Society Foundation Board of Trustees, serving as past Vice-Chairman of the Executive Committee, and currently as Foundation Trustee Liaison to the American Cancer Society National Board of Directors.
Tom Curran, MD, used the example of research advances in childhood medulloblastoma to illustrate the potential and broad impact of cancer research. "We have now learned that cancer is defined by molecular pathways, not the physical location of the tumor. So, what we learn in brain tumor research may be quite useful in how we understand and further research other cancers."

C-Change Members Ellen Sigal and Ron Herberman participate in the Briefing discussion.

C-Change also extends a special thank you to Mark Mendenhall for his efforts in organizing the event. Mendenhall, Program Administrator for the American Association for Cancer Research, provides in-kind staff support to the Research Team.

Hal Moses stresses the importance of RO1 grant funding.

Speaking as a cancer survivor, or in his words, “a member of the club,” Sam Donaldson delivered a lively address, urging the audience to take note of cancer as an issue important to all of us. Given the incidence of cancer faced by all Americans and an increase in life expectancy, he emphasized the importance of cancer issues to their constituents and as a grassroots issue with powerful links to voting decisions.

C-Change extends its appreciation to its Members for the collaborative efforts in helping organize and voicing their support for the Briefing. C-Change also recognizes and thanks Congresswoman Deborah Pryce and her Legislative Assistant, Shiloh Roehl, for their roles in organizing the briefing. Senator Dianne Feinstein and Tamar Magarik provided assistance in securing the support of the Senate Cancer Coalition. In addition to endorsements by the Senate Cancer Coalition and the House Cancer Coalition, several C-Change Members voiced their support of the Briefing (See list below).

C-Change also extends a special thank you to C-Change Members voiced their support of the Briefing.

Calls to Action in Action

At the November Semi-Annual meeting, the Cancer Workforce Team and the State Cancer Plan Team issued “Calls to Action” in a true test of C-Change’s mission - “to leverage the expertise and resources of our membership… to eliminate cancer as a public health problem at the earliest possible time.” The following is an update on activity since November.

Cancer Workforce-Summer Internship Program

Fifteen organizations responded to the Workforce Team’s “Call to Action” by committing to nominate their summer intern to participate in the 2005 pilot program. The application process for the summer interns is currently underway in preparation for the program kick-off at the May 20-21 meeting.

State Cancer Plans-State Assistance

The State Cancer Plans Team issued a “Call to Action,” requesting Member’s organizations to provide one or more states or territories with assistance on specific issues on their comprehensive cancer control plans. More than 20 Members and Partners offered to provide needed assistance to one or more specific states. State Cancer Control Program officials, in conjunction with C-Change Partner Leslie Given of the Centers for Disease Control and Prevention, are in the process of coordinating this assistance.

To learn more about these initiatives, please contact Alison Smith (Workforce) or Gary Gurian (State Plans).

C-Change Funds Educational Column

MEDSURG Nursing and C-Change have joined forces to enlist medical-surgical nurses in the battle against cancer. Sponsored by an educational grant from C-Change, the journal will carry in each issue a column, “Cancer: Caring and Conquering.”

“Medical-surgical nurses are the backbone of our health care delivery system,” commented Connie Curran. “Medical-surgical nurses can join us in the battle against cancer; the life they save may be their own or that of a loved one. I am also hoping that when there is an opportunity to inform, educate, treat, and conquer this terrible illness, medical-surgical nurses will be there,” Curran stated.

Linda H. Yoder, PhD, MBA, RN, AOCN, FAAN will author the column. She is Program Director, Evidence-Based Practice, Outcomes and Research, Education Institute, at Adventist HealthCare in Rockville, MD. Dr. Yoder will report the latest information on cancer screening, prevention, smoking cessation, clinical trials, treatments, resources for nurses and patients, and other pertinent information. The articles will also appear on the journal’s Web site for continuing education credit (www.medsurgnursing.net).

Briefing Co-Sponsors

- American Association for Cancer Research
- American College of Surgeons Commission on Cancer
- American Society for Therapeutic Radiology and Oncology
- American Society of Clinical Oncology
- Association of Pediatric Oncology Social Workers
- Breast Cancer Resource Communities, Inc.
- Cancer Research and Prevention Foundation
- Childhood Cancer Foundation
- Colon Cancer Alliance
- Friends of Cancer Research
- Institute for Alternative Futures
- Intercultural Cancer Council
- Intercultural Cancer Council Caucus
- International Myeloma Foundation
- Lymphoma Foundation of America
- Men’s Health Network
- National Association of Social Workers
- National Coalition for Cancer Research
- The Lung Cancer Alliance
- Oncology Nursing Society
- Paula Kim Consulting
  Translating Research Across Communities
- U.S. Oncology
- University of Colorado Cancer Center
- University of Pittsburgh Cancer Institute, Pittsburgh, PA
- University of Texas M.D. Anderson Cancer Center
New Staff Join C-Change Team

Michaelann Cooke
Administrative Assistant
Michaelann Cooke has joined the C-Change Team as the Office Administrative Assistant. She will oversee the office and support the staff in various organizational and team activities. In past roles, she provided support to leaders in both the not-for-profit and mortgage industries and excels in communication and logistics management.

Cooke commented on her new position. “I am very excited about working for an organization that is committed to conquering cancer. I realize the importance of the C-Change mission and look forward to working with the staff and Members.” As a Washington resident for 7 years, she looks forward to supporting local and national issues.

Cooke holds a bachelors degree in fine arts from the Catholic University of America. Her studies emphasized the history of art and the importance of art in today’s society.

Brian Alexander- Manager of Marketing & Information Services
Brian Alexander has joined C-Change as the Manager of Marketing and Information Services. He will work closely with all of the C-Change staff to help create and maintain a solid technical infrastructure that will benefit both internal data management as well as external communications. His leadership and expertise will be critical to the selection and implementation of intranet tools to support the staff and teams of C-Change.

Alexander noted, “I am pleased to have the opportunity to be part of the C-Change team. I look forward to introducing new technologies that will help the organization manage data and communication networks. Through my interactions with both Members and staff, I hope to assist in increasing the presence of the organization throughout the healthcare industry.”

Alexander brings seven years of experience working in the not-for-profit sector working on both membership management and information technology.

A native of the Washington, DC, area, Alexander holds a Bachelor of Science degree in Business Management from Bowie State University. He has earned a Graduate Certificate in Systems Analysis & Design from the University of Maryland University College, from which he will also receive his Masters degree in Management Information Systems this spring.

Senate Cancer Coalition Looks at Advances in Colorectal Cancer

The U.S. Senate Cancer Coalition held a hearing on March 16 on the importance of colorectal screening and the future of virtual colonoscopy as a screening method. Held as part of National Colorectal Cancer Awareness Month, the hearing received expert testimony from colon cancer survivor Joel Siegel, movie critic for ABC News; Dr. Abraham Dachman, Radiologist and Director of Computed Tomography at the University of Chicago, and author of the first book on virtual colonoscopies; and Dr. George Mensah, Acting Director of the National Center for Chronic Disease Prevention and Health Promotion at Centers for Disease Control and Prevention. C-Change Vice Chair Senator Dianne Feinstein is a leader of the Senate Cancer Coalition.

Armstrong, Tour of Hope, and C-Change to Cross USA Again

Lance Armstrong will again lead a new Tour of Hope cycling team across the country in 2005 to promote cancer awareness. It will be the third year in a row for the Tour, which is sponsored by Bristol-Myers Squibb. C-Change will join the Tour again as a partner for its second straight year of participation.

Armstrong, and a team of 20 cyclists, all of whom will have been touched by cancer in some way, will begin their 3,300 mile trip from San Diego, California, on September 29 and end in Washington, DC, on October 8. Throughout the trip, they will promote the importance of cancer research, participation in clinical trials, and personal cancer awareness.

Anyone interested in becoming one of the 20 riders can apply online at tourofhope.org. C-Change also will have information at a later date about other ways you will be able to participate in the Tour.
### TEAM Priorities

#### Access to Quality Cancer Care

- Publish proceedings and recommendations from the Information and Surveillance Summit
- Finalize and pursue the achievement of the priority recommendations generated through the Surveillance & Information Summit
- Develop patient navigator training programs.

#### Cancer Research

- Convene forums for independent pilot sites who are implementing the National Biospecimen Network Blueprint
- Publish additional papers on the use of surrogate endpoints in removing barriers to drug discovery
- Publish a paper on the role of Academic Medical Centers in drug development
- Conduct Congressional Educational Briefings related to Cancer Research
- Plan an approach to an Economic Impact Study of Cancer

#### Cancer Workforce

- Develop a plan to build a national “Cancer Corps” from the healthcare workforce with the necessary surge capacity and competency to deliver cancer care to an aging population
- Conduct initial phase of Summer Internship Program including three C-Change-sponsored interns and 10 Member-sponsored interns
- Develop a “Careers in Cancer” speakers kit and issue a “Call to Action” to members to help recruit students and healthcare professionals into careers in cancer

#### Clinical Trials

- Develop a module and guidance documents on workforce issues to support state cancer planning efforts and future CCLI workshops
- Develop a guidance document on the cost of conducting clinical trials for use by public and private sector policymakers
- Publish a paper on series of regulatory reforms that will help expedite the clinical trials process and pursue the recommendations outlined in the paper through a member organization
- Develop a model State Clinical Trials Network, designed to increase access and accrual to clinical trials
- Conduct and disseminate the findings of a public and patient focused survey on the attitudes, beliefs and behaviors associated with clinical trial participation
- Develop a clinical trials module for the Phase III Comprehensive Cancer Control Leadership Institute

### Recent Actions Taken / Accomplishments

#### Access to Quality Cancer Care

- Finalizing the Information and Surveillance Summit Report for review and approval by the Board.
- Developing strategies to achieve the Summit priority recommendations through C-Change member/partner organizations and other selected stakeholders
- Convened a work group composed of member/partner organizations with an active interest in patient navigator programs to plan this initiative.
- Developed an outline for the module and solicited stakeholder input

#### Cancer Research

- Continuing to network with interested research centers
- Convening a work group to develop a paper regarding surrogate endpoints in lung cancer
- Completed draft with board approval and journal submission pending
- Conducted a briefing on 3/14/05 on “Funding Cancer Research: Progress, Opportunities, and the Role of Government”
- Evaluating conceptual approaches to an Economic Impact Study

#### Cancer Workforce

- Identifying a planning committee for a 2005 conference
- Evaluating responses to a Request for Proposal to define core competencies in cancer care. Currently identifying expert panel members representing multidisciplinary leaders from academic, scientific, and clinical arenas
- Currently recruiting summer interns

#### Clinical Trials

- Developing speaker’s kit materials for “Call to Action” at the May Semi-Annual meeting
- Drafting module content including workforce assessment tools and an inventory of best practices
- Completing “The Clinical Trials Guidance Document” through a contractual agreement with The Lewin Group. Pending revisions and Board approval prior to publication and dissemination
- Pending Board approval of “Reducing the Regulatory Barriers” prior to publication and dissemination

- Developed and distributed a Request for Proposal (RFP) for the development and implementation of at least one state clinical trials network
- The survey is being conducted under the auspices of the Coalition of National Cancer Cooperative Groups
- Developing the module in conjunction with the National Coalition of Cancer Cooperative Groups

---

*cont. on page 8, Team News*
<table>
<thead>
<tr>
<th>TEAM</th>
<th>Priorities</th>
<th>Recent Actions Taken / Accomplishments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Prevention &amp; Early Detection</td>
<td>Achieve at least two of the priority recommendations generated from the Prevention and Early Detection Summit: 1. Enhance access to and the delivery of cancer prevention and early detection services 2. Gain evidence-based consensus on lung cancer screening and early treatment 3. Work to achieve the remaining communication, promotion of best practices, policy development, and other research-related priority recommendations generated from the Prevention and Early Detection Summit</td>
<td>Planning a multi-sector sector symposium in partnership with the Agency for Health Care Research and Quality for May 19, 2005 Planning a consensus conference in partnership with the Cancer Prevention and Research Foundation, scheduled for April 28-29, 2005 Developing plans to achieve remaining priority recommendations through C-Change member partner/member organizations</td>
</tr>
<tr>
<td>State Cancer Plans</td>
<td>Conduct Planning Assistance Team (PAT) visits in 5 targeted states to enhance comprehensive cancer control program planning and implementation efforts</td>
<td>Identifying 5 states and developing plans for PAT visits</td>
</tr>
<tr>
<td>Tobacco Control</td>
<td>Develop a tobacco control module for use at a series of Phase III Comprehensive Cancer Control Leadership Institute  In conjunction with the Prevention and Early Detection Team, issue a Call-to-Action challenging members to convene their major organizational meetings in smoke free cites or jurisdictions Developing a multi-sector action plan to address nagging tobacco control issues at the federal and state levels in conjunction with ASCO Actively engage C-Change member organizations and other stakeholders in addressing tobacco control issues in targeted states and other jurisdictions Provide assistance to five targeted states to help them address a specific tobacco control issue [e.g., clean indoor air legislation] Provide assistance to five targeted states designed to enhance the integration of state tobacco control and cancer control programs and facilitate the funding of cancer control plans with state tobacco tax revenues</td>
<td>Developed an outline for the tobacco control module and soliciting stakeholder input Developing a smoke free meeting resolution “Call-to-Action” for the May Semi-Annual meeting Convened a series of stakeholder meetings and have begun the process of developing the multi sector action plan Developing a series of member/partner “calls to action” and associated toolkits for presentation at future semi-annual meetings Developing and implementing the state specific issue intervention Developing and implementing an integration initiative</td>
</tr>
</tbody>
</table>